Navigation Links
Vanderbilt scientists report first effective medical therapy for rare stomach disorder
Date:11/25/2009

A drug used to treat colorectal cancer also can reverse a rare stomach disorder and should be considered first-line therapy for the disease, researchers at Vanderbilt University Medical Center report this week.

Mntrier's disease causes thickening of the stomach lining, severe abdominal pain, nausea and vomiting, as well as anemia and swelling in the feet and ankles due to protein loss. Patients are at increased risk for gastric cancer. Previously, the only effective treatment was gastrectomy surgical removal of the stomach.

The targeted cancer drug cetuximab, brand name Erbitux, relieved symptoms of severe Mntrier's disease in seven patients who completed a one-month course of treatment. Four of them showed near-complete remission, the Vanderbilt researchers report in the Nov. 25 issue of the journal Science Translational Medicine.

"We have identified the first effective medical therapy for this disorder," said Robert Coffey, M.D., Ingram Professor of Cancer Research and the paper's senior author.

Erbitux is a monoclonal antibody that blocks the binding of transforming growth factor-alpha, or TGF-alpha, a signaling protein, to the epidermal growth factor (EGF) receptor. Patients with Mntrier's disease have abnormally high levels of TGF-alpha.

In studies dating back 20 years, Coffey and his colleagues found that TGF-alpha causes proliferation of the stomach lining and stimulates mucous production while suppressing acid secretion. Transgenic mice that over-express TGF-alpha in the stomach exhibit all of the hallmarks of Mntrier's disease.

The current study involved nine patients who were considering gastrectomy. Two patients dropped out of the study, but the rest experienced significant relief of symptoms within hours or days after beginning treatment. All seven continued taking the drug after the monthlong study ended.

Of the four patients who experienced near-complete remission of the disease, one of them, and the other three patients in the study, later underwent gastrectomy. Two patients are no longer taking the drug, and one of them has a normal stomach and remains symptom-free two years later, Coffey said.


'/>"/>

Contact: Bill Snyder
william.snyder@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Ovarian Cancer Coalition Partners With Consuelo Vanderbilt Costin
2. Vanderbilt Experts For Health Care Debate
3. Vanderbilt joins national consortium to develop new cancer therapies
4. Vanderbilt researchers pioneer an advanced sepsis detection and management system
5. NIH-funded Vanderbilt Research Seeks Ways to Avoid Information Overload in Health Care Choices Among Seniors
6. Vanderbilt University Medical Center and Waters Collaborate on Tissue Imaging Research Using SYNAPT HDMS
7. Vanderbilt Medical Center chosen as Evidence-based Practice Center
8. Vanderbilt nets brain gene research center
9. Childrens Hospital Oakland scientists discover soy component may be key to fighting colon cancer
10. BIDMC scientists awarded grants from Michael J. Fox Foundation for Parkinsons research
11. Scientists find molecular trigger that helps prevent aging and disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... dynamic telemedicine solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable ... product is an extension to RMT technology that delivers HD, dynamic, streaming ultrasound ...
(Date:1/19/2017)... ... 19, 2017 , ... WholeHealth is announcing their participation in ... Andrew Petersen and Trish Henrie-Barrus will be present Saturday and Sunday in the ... , “We know it’s easy to get carried away when you’re having ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... dermatologist by the American Board of Dermatology and fellowship trained Mohs and cosmetic ... National Institutes of Health, Dr. Li completed his internship in internal medicine at ...
(Date:1/19/2017)... ... January 19, 2017 , ... Bio-Optronics Inc. is ... modern CTMS workflow designed to seamlessly integrate and streamline the way researchers prepare ... single page, maximizing usability and improving efficiency significantly for users – a first ...
(Date:1/19/2017)... ... 19, 2017 , ... Students interested in video can get a jump start ... will earn a $1,000 scholarship and have his or her video posted on the ... is May 31, with the winner announced on June 9. , The competition is ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 ... appears serious about reducing the FDA,s regulatory strictness ... in the medical drug industry, many of the ... new clinical trials and development of advanced drug ... ahead with recent developments include:  Moleculin Biotech, Inc., ...
(Date:1/19/2017)... CLEVELAND , Jan. 18, 2017  ViewRay, ... the world,s first and only clinical MRI-guided radiation ... gross proceeds of approximately $26.1 million through a ... Puissance Capital Management led the financing and was ... OrbiMed Advisors, LLC and Kearny Venture Partners, and ...
(Date:1/19/2017)...   Synthetic Biologics, Inc. (NYSE MKT: ... to preserve the microbiome to protect and restore ... initiate a Phase 2b/3 adaptive pivotal trial for ... designed to reduce methane production by certain microorganisms ... treat the underlying cause of irritable bowel syndrome ...
Breaking Medicine Technology: